Shares of OraSure Technologies were riding high in July after the company gained FDA approval to market its over-the-counter HIV testing kit. The stock's value has eroded since then, however, and is now at a 52-week low after its Q4 earnings results sent shares down more than 13% in intraday trading. In this video, health care analyst Max Macaluso reviews OraSure's 2012 results and what investors should watch in upcoming quarters.
The Motley Fool's chief investment officer has selected his No. 1 stock for the next year. Find out which stock it is in our brand-new free report: "The Motley Fool's Top Stock for 2013." I invite you to take a copy, free for a limited time. Just click here to access the report and find out the name of this under-the-radar company.
Editor's note: At 1:08, Max meant to say that analyst estimates for Q1 were more than $23 million, according to Yahoo! Finance -- not $37 million. The Fool regrets the error.
The article OraSure Earnings: What Happened? originally appeared on Fool.com.
Max Macaluso, Ph.D. has no position in any stocks mentioned. The Motley Fool has no position in any of the stocks mentioned. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.